Advice
in the absence of a submission from the holder of the marketing authorisation:
selumetinib (Koselugo®) is not recommended for use within NHSScotland.
Indication under review: as monotherapy for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult patients with neurofibromatosis type 1 (NF1).
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice354KB (PDF)
Medicine details
- Medicine name:
- selumetinib (Koselugo)
- SMC ID:
- SMC2987
- Indication:
As monotherapy for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult patients with neurofibromatosis type 1 (NF1).
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 October 2026